Seagen tees up with Dutch I/O out­fit, en­gi­neers $700M deal for EGFR as­set

Amid re­ports that Mer­ck was go­ing to ac­quire Seagen, the Seat­tle com­pa­ny de­cid­ed to do its own M&A — se­cur­ing a back-heavy deal.

The an­ti­body-drug con­ju­gate pow­er­house an­nounced bright and ear­ly Mon­day that it would be shelling out as much as $700 mil­lion to LA­VA Ther­a­peu­tics, a Nether­lands-based gam­ma delta T cell en­gager biotech, for its EGFR-tar­get­ing drug can­di­date.

The can­di­date, called LA­VA-1223, is in an ad­vanced pre­clin­i­cal stage, LA­VA CEO Steve Hurly tells End­points News.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN